Effects of cardiopulmonary bypass on immunoglobulin G antibody titres after SARS-CoV2 vaccination

Ryosuke Hayashi, Yoshiyuki Takami, Hidetsugu Fujigaki, Kentaro Amano, Yusuke Sakurai, Kiyotoshi Akita, Koji Yamana, Atsuo Maekawa, Kuniaki Saito and Yasushi Takagi

Abstract

OBJECTIVES: Patients with cardiovascular disease are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Although SARS-CoV2 vaccination may be effective, its impact on surgical patients is not well studied. We investigated the effects of cardiovascular surgery, especially under cardiopulmonary bypass (CPB), on the antibody titres after SARS-CoV2 vaccination.

METHODS: A prospective observational study was designed for patients undergoing surgery between July and November 2021. The immunoglobulin G against the receptor-binding domain was measured and antibody preserved rate (APR) was calculated from perioperative titres comparison.

RESULTS: Enrolled 63 study patients were divided into 39 undergoing surgery with CPB (Group CPB) and 24 without CPB (Group None). Preoperative vaccines were BNT162b2 (Pfizer/BioNTech) (n = 58, 92%) and mRNA-1273 (Moderna) (n = 5, 8%). While immunoglobulin G
against the receptor-binding domain titres did not significantly decrease after surgery in Group None, they decreased significantly in Group CPB from 21.80 [11.15, 37.85] to 11.95 [6.80, 18.18] U/ml (P < 0.001) a day after surgery, 11.40 [7.85, 22.65] U/ml (P < 0.001) 14 days after surgery and 7.60 [4.80, 17.60] U/ml (P < 0.001) a month after surgery. The APRs a day after the surgery were significantly lower in Group CPB (0.46 [0.41, 0.60]) than in Group None (0.80 [0.68, 0.87]) (P < 0.001).

CONCLUSIONS: The SARS-CoV2 antibody titres significantly decreased with lower APRs immediately after surgery under CPB. Based on our informative results, careful considerations of vaccination schedule might be required for surgery under CPB.

Keywords: Severe acute respiratory syndrome coronavirus 2 • Coronavirus disease 2019 • Cardiopulmonary bypass • IgG antibody • mRNA vaccine

**INTRODUCTION**

Since the first outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in December of 2019, a fear and a threat impacted humanity socially and economically. The SARS-CoV2 is a type of coronavirus which accounts for series of symptoms including fever, myalgia, headache, dyspnoea, cough, sore throat, smell or taste abnormalities, and severe acute respiratory syndrome (SARS) which World Health Organization officially designated as Coronavirus disease 2019 (COVID-19) in February 2020 [1–3]. In a field of cardiovascular surgery, patients suffering from the cardiovascular disease frequently have comorbid medical conditions which are all aggravating factors of COVID-19, including elder, diabetes mellitus, hypertension, chronic respiratory disease and chronic kidney disease [4, 5].

Although pharmaceutical treatments are being developed around the globe, vaccination plays a key role in the prevention of COVID-19. World Health Organization recommends the vaccination for people older than 18 years old, especially for those with vulnerable medical conditions [6]. As of 2021, 3 vaccines are approved in Japan against SARS-CoV2. They are BNT162b2, mRNA-1273 and ChAdOx1-S, developed by Pfizer/BioNTech, Moderna and Oxford/AstraZeneca, respectively. The former 2 are messenger ribonucleic acid (mRNA) vaccines and the latter one is an adenovirus vectored vaccine [7–9].

To determine the efficacy of the SARS-CoV2 vaccine, a serological antibody correlation with vaccine-induced immune response has been reported previously [10]. While the humoral responses after the SARS-CoV2 vaccination in the healthy subjects have been reported, there are no studies related to patients undergoing cardiovascular surgery. Thus, the present study investigated the effects of cardiovascular surgery, especially under cardiopulmonary bypass (CPB), on the patients' immunoglobulin G (IgG) antibody titres after SARS-CoV2 vaccination.

**PATIENTS AND METHODS**

**Ethics statement**

This study was approved by Fujita Health University Ethics Committee (HM 21-164). It was also conducted with the informed consent, according to the ethical guidelines for clinical study published by the Ministry of Health and the Declaration of Helsinki.

**Study patients**

This prospective observational study in the patients who had already been vaccinated and underwent surgery at Fujita Health University between July 2021 and November 2021.

In this study, patients were divided into 2 groups. The first group included the patients undergone surgery without CPB (Group None), as opposed to the group including the patients undergone surgery with CPB (Group CPB).

**Patient management**

In all patients of Group CPB and some patients in Group None, anaesthesia was induced with intravenous midazolam, fentanyl and vecuronium bromide, followed by endotracheal intubation. Anaesthesia was subsequently maintained with sevoflurane, propofol, remifentanil and vecuronium bromide. CPB was performed using a heparin-coated circuit and a membrane oxygenator. In Group CPB, oxygen concentration and ventilation frequency were adjusted to maintain normoxemia (>90 mmHg) and normocapnia (35–45 mmHg). Cardiac arrest was induced by blood-cardiopilegia. Pump flow and mean arterial pressure were maintained at 2.5 l/min/m² and above 60 mmHg, respectively, with norepinephrine. Inotropic support with epinephrine was used during CPB weaning.

In some patients of Group None, the surgery was performed with local anaesthesia and sedation with propofol and dexmedetomidine without endotracheal intubation. In both groups, patients were transferred to the intensive care unit (ICU) after the surgery, where they were extubated following institutional criteria.

**Data collection and SARS-CoV2 vaccination**

The patient characteristics were collected and analysed from electronic health records, including age at surgery, sex, smoking history and comorbidity (hypertension, hyperlipidaemia, diabetes mellitus, respiratory function, and presence of chronic kidney disease). The surgical procedures performed (type of surgery), a

### ABBREVIATIONS

| APRs | Antibody preserved rates |
| COVID-19 | Coronavirus disease 2019 |
| CPB | Cardiopulmonary bypass |
| ICU | Intensive care unit |
| IgG | Immunoglobulin G |
| mRNA | Messenger ribonucleic acid |
| RBD-IgG | IgG against the receptor-binding domain |
| SARS | Severe acute respiratory syndrome |
| SARS-CoV2 | Severe acute respiratory syndrome coronavirus 2 |
total operation duration, a CPB duration, a cardiac arrest duration, a selective cerebral perfusion duration, total amount of bleeding, an amount of blood transfusion administered, a duration of tracheal intubation, time in ICU and length of hospital stay were recorded.

The SARS-CoV2 vaccination dates and the types of vaccine were interviewed in each patient and were also verified with the vaccination certificates issued by each healthcare institute. Patients with 2 doses of vaccine are enrolled in the study, but those with third booster vaccination are not included. We also checked the history of possible SARS-CoV2 exposure in each patient. The check-ups for SARS-COV2 infection or COVID-19 disease were performed before admission, about 1 week, 2 weeks and 1 month after discharge.

**Antibody titre measurement**

Blood samples for antibody titre measurement were taken at 4 correspondent times, including prior to the surgery, a day after the surgery (7–16 hours after surgery), 2 weeks after surgery and a month after surgery, as visualized in Supplementary Material S1. In addition, when a patient received any blood transfusion, the segment tubes from each pack of the red blood cells were taken for antibody titre measurement.

The IgG against the receptor-binding domain (RBD-IgG) was measured as an antibody titre from each blood samples. A chemiluminescent enzyme immunoassay using an Accuraseed COVID-19 antibody reagent with the Accuraseed automated immunoassay system from FUJIFILM Wako Pure Chemical Corporation was used for the measurement. The details of the method and performance such as limit of quantification, precision, and accuracy were published previously [10].

**Statistical analysis**

Categorical data are represented as either a number or a percentage (%) and compared between groups by Fisher’s exact test. A level of IgG transition among various times, before and after the surgery, was observed in each group. The differences in change of IgG levels were compared between the 2 groups. Ordinal variables were represented as median with interquartile range. These noncategoric variables were written in the form of median with interquartile range and compared between groups by either a parametric Student’s t-test or a nonparametric test, the Mann–Whitney U-test. A correlation between 2 variables were analysed using Spearman’s rank correlation coefficient. All statistical analyses were performed with statistical software ‘EZR’ (Easy R) available on website (http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html) [11]. A P-value of <0.05 was considered statistically significant.

**RESULTS**

Between July 2021 and November 2021, there were total of 129 surgical operations performed in our institute. There were 24 unplanned emergency or urgent operations, which were excluded from the research. Twenty-two candidates did not consent to participate in the research, either with their will or lack of ability to do so. Twenty candidates had not vaccinated before the admission. A total of 63 subjects were enrolled to this study (Fig. 1). The patients in Group None (n = 24) underwent endovascular aortic repair (n = 17), off-pump coronary artery bypass grafting (n = 4), transcatheter aortic valve replacement (n = 2) or vascular surgery(n = 1). The patients in Group CPB (n = 39) underwent on-pump beating coronary artery bypass grafting (n = 12), conventional coronary artery bypass grafting (n = 4), valve procedure (aortic valve replacement alone; n = 2 and mitral valve procedure alone; n = 5), aortic procedure (n = 6) and combined procedures (n = 15), as presented in Table 1. The patient characteristics were not statistically different between the 2 groups, except for smoking history, as also shown in Table 1.

No study patients had past diagnosis of SARS-CoV2 infection based upon our routine check-ups for COVID-19 disease. As for
type of SARS-CoV2 vaccines, BNT162b2 (Pfizer/BioNTech) was administered in 58 patients (92%) and mRNA-1273 (Moderna) was administered in 5 patients (8%). The days between the last vaccination and the surgery were significantly longer in Group None (50.25, 91.00 days) than in Group CPB (49.00, 24.50, 75.00 days) (P = 0.031), as shown in Table 2.

As shown in Table 2 and Fig. 2, the antibody RBD-IgG titres in Group CPB decreased significantly from 31.85 [18.95, 80.07] U/ml before surgery to 28.00 [9.25, 60.40] U/ml (P = 0.15) a day after surgery and 17.50 [13.60, 20.30] U/ml (P = 0.23) 14 days after surgery. However, the RBD-IgG titres in Group None did not significantly decrease from 36.85 [18.95, 80.07] U/ml before surgery to 28.00 [9.25, 60.40] U/ml (P = 0.15) a day after surgery and 17.50 [13.60, 20.30] U/ml (P = 0.23) 14 days after surgery. However, the RBD-IgG titres in Group None decreased significantly to 22.50 [11.12, 39.90] U/ml (P = 0.03) a month after surgery, although those were significantly higher than those in Group CPB (P = 0.002). As also shown in Table 2, surgery-related bleeding was significantly more in Group CPB than in Group None; therefore, transfused red blood cells were significantly more in Group CPB. However, the RBD-IgG titres contained in the transfused red blood cells were 57.80 [12.32, 123.42] U/ml in Group None and 48.70 [22.30, 77.85] U/ml in Group CPB (P = 0.835).

We labelled antibody preserved rate (APR), calculated from the ratio between the antibody titres before and after the surgery, for the perioperative titres’ comparison. As shown in Fig. 3, the APRs a day after the surgery were significantly lower in Group CPB (0.46 [0.41, 0.60]) than in Group None (0.80 [0.68, 0.87]) (P < 0.001). Also, the APRs a month after the surgery were significantly lower in Group CPB (0.43 [0.31, 0.60]) than in Group None (0.58 [0.48, 0.75]) (P = 0.05). However, the APRs 14 days after the surgery were similar between the 2 groups (P = 0.77): Group None: 0.65 [0.30, 0.92] and Group CPB: 0.52 [0.45, 0.70].

No significant correlations between the vaccination to surgery days and the APRs in both groups a day after (Spearman correlation; Group None: r = -0.003, P = 0.99 and Group CPB: r = -0.122, P = 0.48) and 14 days after (Spearman correlation; Group None: r = -0.517, P = 0.16 and Group CPB: r = -0.144, P = 0.42) the surgery were observed, as shown in Fig. 4. At a month after the surgery, however, a positive correlation between the interval of vaccination to surgery and the APR was observed in Group CPB (Spearman correlation r = 0.488, P < 0.01) but not in Group None (Spearman correlation r = 0.131, P = 0.60), as shown in Supplementary Material S2.

There were no relationships between the types of vaccine and the APRs, as shown in Table 3. The APRs a day after surgery were 0.82 [0.41, 0.80] in patients vaccinated with BNT162b2 and 0.59 [0.44, 0.89] in those vaccinated with mRNA-1273 (P = 0.76). At 2 weeks after surgery, the APRs were 0.48 [0.00, 0.65] (BNT162b2) and 0.43 [0.25, 0.57] (mRNA-1273) (P = 0.85). At a month after the surgery, they were 0.51 [0.27, 0.62] (BNT162b2) and 0.34 [0.22, 0.40] (mRNA-1273), respectively (P = 0.43).

**DISCUSSION**

To our best knowledge, this is the first report investigating the effects of cardiovascular surgery under CPB on the IgG antibody titre after SARS-CoV2 vaccination. The main findings of our study were as follows: (i) There was significant reduction, up to half of the preoperative values, of SARS-CoV2 antibody titres immediately after the surgery in Group CPB. (ii) After a month, antibody titres reduced significantly in both groups. (iii) Although an interval from vaccination to surgery was irrelevant to APR in
Patients queueing cardiovascular surgery are vulnerable to SARS-CoV2 infection not only because of their cardiovascular disease, but along with their background and comorbidities related to their lifestyles. They are recommended for vaccination and priority is high among them [5, 12].

Aside from the novel SARS-CoV2 mRNA vaccine, pre-existing live nor inactive vaccine’s information regarding perioperative vaccination is limited. Even annual influenza vaccination after open heart surgery varies among institutions, lacking consensus [13, 14].

The inflammatory and immune system are known to get altered after any surgery, due to general anaesthesia and its invasive procedure [15, 16]. Furthermore, CPB used in cardiovascular surgery can supplementally disturb those systems [14, 17–19]. Vergales et al. [14] reports that the antibody titres did not vary among diphtheria, tetanus, polio1, polio3 or Haemophiles influenzae vaccination between before and after the congenital cardiac surgery; however, they had reduced significantly among

---

**Table 2: Measured results**

|                                | Group None                          | Group CPB                          | P-Value   |
|--------------------------------|-------------------------------------|------------------------------------|-----------|
| Time between last vaccination to surgery, day | 68.50 [50.25, 91.00]                | 49.00 [24.50, 75.00]               | 0.031     |
| Vaccination type, BNT162b2    | 22 (91.7)                           | 36 (92.3)                          | 1.000     |
| Antibody titres, unit/ml      |                                     |                                    |           |
| Prior to surgery              | 36.95 [18.95, 80.07]                | 21.60 [11.15, 37.85]               | 0.050     |
| At 1 day after surgery        | 28.00 [9.25, 60.40]                 | 11.95 [6.80, 18.18]                | 0.011     |
| At 14 days after surgery      | 17.50 [13.60, 20.30]                | 11.40 [7.85, 22.65]                | 0.522     |
| At 1 month after surgery      | 22.50 [11.12, 39.90]                | 7.60 [4.80, 17.60]                 | 0.002     |
| Operation time, min           | 172.00 [80.00, 232.50]              | 344.00 [310.00, 424.50]            | <0.001    |
| Cardiopulmonary bypass, min   | 163.00 [134.00, 211.00]             |                                    |           |
| Aortic cross-clamp, min (n = 25) | 128.50 [103.25, 164.00]          |                                    |           |
| Selective cerebral perfusion, min (n = 8) | 51.00 [32.00, 108.00]          |                                    |           |
| Bleeding, ml                  | 200.00 [180.00, 500.00]             | 1274.00 [879.50, 2026.50]          | <0.001    |
| Transfusion                   |                                     |                                    |           |
| Red blood cells, unit         | 4.00 [2.00, 6.00]                   | 11.00 [6.00, 14.00]                | 0.005     |
| Fresh frozen plasma, unit     | 10.00 [7.00, 13.00]                 | 12.00 [8.00, 16.00]                | 0.544     |
| Platelet concentrated, unit   | 20.00 [20.00, 30.00]                |                                    |           |
| Antibody contained in transfusion, unit/ml | 57.80 [12.32, 123.42]           | 48.70 [22.30, 77.85]               | 0.835     |
| Tracheal intubation period, h | 0.00 [0.00, 0.75]                   | 14.00 [5.00, 16.50]                | <0.001    |
| ICU stay, days                | 0.00 [0.00, 1.00]                   | 3.00 [2.00, 3.50]                  | <0.001    |
| Hospital stay, day            | 8.00 [7.00, 15.50]                  | 23.00 [19.00, 32.00]               | <0.001    |

Data are presented as n (%) or interquartile range.

ICU: intensive care unit.

---

**Figure 2: Antibody titres (U/ml) of Group None and Group CPB at various sample timings.**

Group None, positive correlation was observed between the interval and APR at 1 month after the surgery in Group CPB.

---

R. Hayashi et al. / Interactive CardioVascular and Thoracic Surgery 5
Table 3: Relationship between vaccination type and antibody preserved ratios

| APR                     | BNT162b2 (n = 55)     | mRNA-1273 (n = 5)      | P-Value |
|-------------------------|-----------------------|------------------------|---------|
| At 1 day after surgery  | 0.82 [0.41, 0.80]     | 0.59 [0.44, 0.89]      | 0.764   |
| At 14 days after surgery| 0.48 [0.00, 0.65]     | 0.43 [0.25, 0.57]      | 0.846   |
| At 1 month after surgery| 0.51 [0.27, 0.62]     | 0.34 [0.22, 0.40]      | 0.432   |

Data are presented in interquartile range.
APR: antibody preserved rate; CPB: cardiopulmonary bypass.
Bordetella and hepatitis B vaccination. With that in mind, significant reduction of SARS-CoV2 antibody titres in Group CPB but not in Group None in our result is very informative. Although the effect of CPB on the antibody titres was not significantly apparent 14 days after the surgery, there was greater reduction of APR in Group CPB than in Group None after a day and a month, as shown in Figs. 2 and 3. It is also informative that the antibody titres a month after surgery reduced significantly in both groups. This might reflect the natural wane off of an antibody titre reported in the literature [10, 20, 21] with possible acceleration affected by surgical intervention. A decrease of 75–93% IgG titres after 3 weeks to 3 months after second dose vaccination in healthy subjects is reported previously [10, 20, 21]. Although standard primary SARS-CoV2 vaccination protocol is twice dosage, a third booster or an additional dose is proposed [22, 23]. Our finding might suggest the need of third additional vaccination among post-cardiovascular surgery patients.

A period from vaccination to surgery seemed irrelevant as of APRs in Group None, suggesting that there was no alteration in vaccine acquired immunity after surgery without CPB. However, since a positive correlation between the interval from vaccination to surgery and the APR at a month after the surgery was observed in Group CPB, a careful scheduling of a vaccination may be proposed for surgery under CPB. The lower antibody titres and lower APRs in Group CPB compared to that in Group None a day after and a month after surgery, as shown in Figs. 2 and 3, might have been associated with lower antibody titres before surgery and shorter interval from vaccination to surgery in Group CPB than in Group None. One should bear in mind that the recommended vaccination schedule prior to the surgery is at least 7 days [24, 25], with the context of possible side effects and reactogenicity of the vaccine which approximately takes 10–14 days [7, 8, 25]. No patient had vaccination less than a week before surgery in our study.

Limitations

There are number of limitations in this research. First, a small number of study sample size influenced the statistical result, making it difficult to analyse the underlying conditions. Also, conduction of single institution research could have added sampling bias. The second limitation is different subject characteristics between 2 comparison groups. Smoking history and vaccination to surgery interval were statistically implicated different in background characteristics. Factors of surgical intervention also weighed more on Group CPB, such as more operation time, more tracheal intubation period, more ICU stay, and more hospital stay, shown in Table 2. The reason behind it is because Group None consisted mostly non-cardiac surgery such as EVAR, TEVAR, and TAVI, contrarily to Group CPB consisted aortic procedure and combined procedures. Third limitation is that study was not a direct comparison between cardiac surgery with and without CPB. Although the difference between Group CPB and Group None in our study may not only be attributed to the usage of CPB, the data of Group CPB in our study is informative in the continuing era of fight against COVID-19 pandemic, armed with new type of mRNA vaccines triggering an immune response. Fourth, the patients enrolled in this study never had third booster dose within the follow-up period. Therefore, our result may be limited since the evidence and data about SARS-CoV2 vaccination are being updated day by day. The fifth limitation is the quantitative measurement of vaccination efficacy. Some advocate RBD-IgG may not necessarily reflect the neutralizing activity against SARS-CoV2 [21]. Although debatable, our previous finding suggests that the monitor of RBD-IgG is plausible and prompt predicative tool to determine the immunogenicity of SARS-CoV2 vaccination [10].

CONCLUSIONS

A significant reduction of antibody acquired by SARS-CoV2 vaccination was perceived immediately after the surgery with CPB. A positive correlation between the interval from vaccination to surgery and the APR at a month after the surgery was observed in Group CPB, although there was similar tendency of reduction in APR in the patients undergoing with and without CPB. Based upon our informative results, careful considerations of vaccination schedule might be required for the patients undergoing surgery with CPB.

The analysis obtained in this research could support the argument of additional vaccination among perioperative patients. Further study is demanded to provide better preventive medication for perioperative patients. A shared decision-making on additional dose of SARS-CoV2 vaccination among perioperative patients is desired.

SUPPLEMENTARY MATERIAL

Supplementary material is available at ICVTS online.

ACKNOWLEDGEMENT

We would like to thank FUJIFILM Wako Pure Chemical Corporation for providing the Accuraseed COVID-19 antibody reagent.

Conflict of interest: Kuniaki Saito belongs to an endowed department sponsored by FUJIFILM Wako Pure Chemical Corporation. The authors report no other conflict of interest.

Data Availability Statement

All relevant data are within the manuscript and its Supporting Information files.

Author contributions

Ryosuke Hayashi: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Writing—original draft; Writing—review & editing. Yoshiyuki Takami: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Writing—original draft; Writing—review & editing. Hidetsugu Fujigaki: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Writing—original draft; Writing—review & editing. Kentaro Amano: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Writing—original draft; Writing—review & editing. Yusuke Sakurai: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Writing—original draft; Writing—review & editing. Kiyotoshi Akita: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Writing—review & editing. Koji Yamana: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Validation; Writing—
review & editing. **Atsuo Maekawa:** Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Validation; Writing—review & editing. **Kuniaki Saito:** Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Visualization; Writing—review & editing.

**Reviewer information**

Interactive CardioVascular and Thoracic Surgery thanks Tomonobu Abe, Lucio Cagini and the other anonymous reviewer(s) for their contribution to the peer review process of this article.

**REFERENCES**

[1] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.

[2] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

[3] Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients withConfirmed Coronavirus Disease (Covid-19). 2020.

[4] Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T et al. Features of severe covid-19: a systematic review and meta-analysis. Eur J Clin Invest 2020;50.e13378.

[5] Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe Covid-19: Information for Healthcare Providers, 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.

[6] World Health Organization. Covid-19 Advice for the Public: Getting Vaccinated. World Health Organization, 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice.

[7] Polack FP, Thomas SJ, Kitchin N, Absalon J, Guttmann A, Lockhart S et al. C4591001 Clinical Trial Group. Safety and efficacy of the bnt162b2 MRNA covid-19 vaccine. N Engl J Med 2020;383:2603–15.

[8] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al. Efficacy and safety of the mrna-1273 SARS-CoV-2 vaccine. N Engl J Med 2020;384:403–16.

[9] Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ et al.; IVY Network. Comparative effectiveness of Moderna, Pfizer-Biontech, and Janssen (johnson & johnson) vaccines in preventing covid-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. Morb Mortal Wkly Rep 2021;70:1337–43.

[10] Fujigaki H, Yamamoto Y, Koseki T, Banno S, Ando T, Ito H et al. Antibody responses to bnt162b2 vaccination in Japan: monitoring vaccine efficacy by measuring IgG antibodies against the receptor-binding domain of SARS-CoV-2. Microbiol Spectr 2022;10:e0118121.

[11] Kanda Y. Investigation of the freely available easy-to-use software ‘ezr’ for medical statistics. Bone Marrow Transplant 2013;48:452–8.

[12] American Heart Association. Heart Disease and Stroke Medical Experts Urge Public to Get Covid-19 Vaccinations. Dallas, TX, USA: American Heart Association, 2021.

[13] Short JA, Van Der Walt JH, Zoaenni DC. Immunization and anesthestia—an international survey. Paediatr Anaesth 2006;16:514–22.

[14] Vergales J, Dean P, Raphael J, Frank D, Narahari A, Hekking T et al. Cardiopulmonary bypass and infant vaccination titers. Pediatrics 2020;145.

[15] von Dossow V, Sander M, MacGill M, Spies C. Perioperative cell-mediated immune response. Front Biosci 2008;13:3676–84.

[16] Kurosawa S, Kato M. Anesthesit, immune cells, and immune responses. J Anesth 2008;22:263–77.

[17] Sabrina C, Cathy W, Rozheb T. Abstracts from the American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Congenit Heart Dis 2014;9:453–95.

[18] Tajima K, Yamamoto F, Kawazoe K, Nakatani I, Sakai H, Abe T et al. Cardiopulmonary bypass and cellular immunity: changes in lymphocyte subsets and natural killer cell activity. Ann Thorac Surg 1993;55:625–30.

[19] Habermehl P, Knuf M, Kampmann C, Mannhardt W, Schranz H, Kuroczynski W et al. Changes in lymphocyte subsets after cardiac surgery in children. Eur J Pediatr 2003;162:15–21.

[20] Kato H, Miyakawa K, Ohtake N, Yamaoka Y, Yamazaki E et al. Vaccine-induced humoral and cellular immunity against SARS-CoV-2 at 6 months post bnt162b2 vaccination. medRxiv 2021. https://doi.org/10.1101/2021.10.30.21265693.

[21] Malipiero G, D’Agaro P, Segat L, Moratto A, Villalta D. Long-term decay of anti-RBD IgG titers after bnt162b2 vaccination is not mirrored by loss of neutralizing bioactivity against sars-cov-2. Clin Chim Acta 2022;524:11–7.

[22] World Health Organization. Interim Statement on Booster Doses for Covid-19 Vaccination. World Health Organization, 2021. https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination—update-22-december-2021.

[23] Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC et al. Considerations in boosting covid-19 vaccine immune responses. Lancet 2021;398:1377–80.

[24] Michael Griffin NM, Taylor J. For Surgeons and Surgical Teams Treating Patients during Covid-19—Endorsement of the Academy Statement. Edinburgh, Scotland, UK: UK Surgical Royal Colleges, 2021.

[25] Merritt-Genore H, Moosdorf R, Gillaspe E, Lother S, Engelman D, Ahmed S et al.; Society of Thoracic Surgeons Workforce on Critical Care. Perioperative coronavirus vaccination-timing and implications: a guidance document. Ann Thorac Surg 2021;112:1707–15.